The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

Nature Chemical Biology

Volumn 6, Issue 8, 2010, Pages 595-601

  Stewart, Michelle L ^a,b   Fire, Emiko ^c   Keating, Amy E ^c   Walensky, Loren D ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; INHIBITOR PROTEIN; PROTEIN BAK; PROTEIN MCL 1; PROTEIN MCL 1 BH3 HELIX; UNCLASSIFIED DRUG; CASPASE 3; CASPASE 7; CROSS LINKING REAGENT; CYTOCHROME C; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PEPTIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; METABOLISM; MITOCHONDRION; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; SYNTHESIS;

HARNESS;

AMINO ACID SEQUENCE; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CASPASE 3; CASPASE 7; CELL SURVIVAL; CROSS-LINKING REAGENTS; CRYSTALLOGRAPHY, X-RAY; CYTOCHROMES C; ENZYME ACTIVATION; HUMANS; IMMUNOPRECIPITATION; JURKAT CELLS; MITOCHONDRIA; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77955891885     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.391     Document Type: Article

References (45)

1. Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443 (1985).
2. Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. Cell 116, 205-219 (2004).
3. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997).
4. Muchmore, S.W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335-341 (1996).
5. Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
6. Zhai, D., Jin, C., Huang, Z., Satterthwait, A.C. & Reed, J.C. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J. Biol. Chem. 283, 9580-9586 (2008).
7. Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259-4264 (2003).
8. Nguyen, M. et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 104, 19512-19517 (2007).
9. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
10. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
11. Wang, G. et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 49, 6139-6142 (2006).
12. Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375-388 (2006).
13. van Delft, M.F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
14. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
15. Zhang, B., Gojo, I. & Fenton, R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99, 1885-1893 (2002).
16. Boisvert-Adamo, K., Longmate, W., Abel, E.V. & Aplin, A.E. Mcl-1 is required for melanoma cell resistance to anoikis. Mol. Cancer Res. 7, 549-556 (2009).
17. Ding, Q. et al. Myeloid Cell Leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer. Cancer Res. 67, 4564-4571 (2007).
18. Lin, X. et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26, 3972-3979 (2007).
19. Meng, X.W. et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 282, 29831-29846 (2007).
20. Taniai, M. et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64, 3517-3524 (2004).
21. Danial, N.N. et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14, 144-153 (2008).
22. Walensky, L.D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
23. Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081 (2008).
24. Walensky, L.D. et al. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell 24, 199-210 (2006).
25. Schafmeister, C., Po, J. & Verdine, G. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891-5892 (2000).
26. Blackwell, H.E. et al. Ring-closing metathesis of olefinic peptides: design, synthesis, and structural characterization of macrocyclic helical peptides. J. Org. Chem. 66, 5291-5302 (2001).
27. Boersma, M.D., Sadowsky, J.D., Tomita, Y.A. & Gellman, S.H. Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain. Protein Sci. 17, 1232-1240 (2008).
28. Day, C.L. et al. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J. Mol. Biol. 380, 958-971 (2008).
29. Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192 (2002).
30. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101, 10000-10005 (2004).
31. Clohessy, J.G., Zhuang, J., de Boer, J., Gil-Gomez, G. & Brady, H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281, 5750-5759 (2006).
32. Han, J., Goldstein, L.A., Gastman, B.R. & Rabinowich, H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281, 10153-10163 (2006).
33. Akgul, C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 66, 1326-1336 (2009).
34. Warr, M.R. & Shore, G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med. 8, 138-147 (2008).
35. Bae, J., Leo, C.P., Hsu, S.Y. & Hsueh, A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275, 25255-25261 (2000).
36. Kim, S.H., Ricci, M.S. & El-Deiry, W.S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 68, 2062-2064 (2008).
37. Ricci, M.S. et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12, 66-80 (2007).
38. Bird, G.H., Bernal, F., Pitter, K. & Walensky, L.D. Chapter 22 Synthesis and biophysical characterization of Stabilized Alpha-helices of BCL-2 Domains. Methods Enzymol. 446, 369-386 (2008).
39. Pitter, K., Bernal, F., LaBelle, J.L. & Walensky, L.D. Chapter 23 Dissection of the BCL-2 family signaling network with Stabilized Alpha-Helices of BCL-2 Domains. Methods Enzymol. 446, 387-408 (2008).
40. Otwinowski, Z. & Minor, W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
41. Storoni, L.C., McCoy, A.J. & Read, R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432-438 (2004).
42. Adams, P.D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002).
43. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
44. Lynch, V.M., Tanaka, T., Fishpaugh, J.R., Martin, S.F. & Davis, B.E. Structure of (+/-)-(1R*,4S*,6S*)-1-benzyloxy-4,8,11,11- tetramethyl-6-phenylthio-bicyclo[5.3.1]undec-7-en-3-one. Acta Crystallogr. C 46, 1351-1353 (1990).
45. Davis, I.W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).